BioMedNewsBreaks

WednesdayJan 14, 2026 9:40 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has licensed regulatory-grade real-world evidence drawn from more than 70,000 U.S. patients treated with intravenous ketamine or nasal S-ketamine for depression and suicidal ideation to support its application for Accelerated Approval of NRX-100, a preservative-free ketamine, under Fast Track Designation. The dataset, provided by Osmind, includes nearly one million treatment sessions and extensive longitudinal safety and effectiveness data and will be submitted to the U.S. Food and Drug Administration following a 2025 policy update allowing de-identified real-world evidence. NRx is seeking approval of NRX-100 for the treatment of suicidal ideation in depression, including bipolar…

Continue Reading

WednesdayJan 14, 2026 9:10 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026

Oragenics (NYSE American: OGEN) announced that it will present at the upcoming Sequire Investor Summit 2026, scheduled for Jan. 20–22, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. During the conference, the Company plans to highlight its novel approach to addressing the significant unmet medical need in concussion and mild traumatic brain injury, including progress toward advancing its ONP-002 clinical program into Phase 2a studies, an area where no approved drug therapies currently exist, according to Oragenics Chief Executive Officer Janet Huffman. To view the full press release, visit https://ibn.fm/Gn84M About Oragenics, Inc. Oragenics, Inc. is a…

Continue Reading

TuesdayJan 13, 2026 10:30 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season

NanoViricides, Inc. (NYSE American: NNVC) said the current severe influenza wave underscores the urgent need for broad-spectrum antiviral therapies capable of addressing influenza, RSV, coronaviruses and other respiratory viruses, citing limitations of seasonal vaccines and existing antivirals that face timing constraints and resistance risks. The Company highlighted its Phase II-stage drug candidate NV-387, a broad-spectrum nanoviricide designed to mimic host-cell features viruses rely on to infect cells, which management believes positions it as a potential first-line, empirical therapy for viral acute and severe acute respiratory infections, with demonstrated preclinical activity against influenza, RSV and coronaviruses and potential applicability across a…

Continue Reading

TuesdayJan 13, 2026 9:40 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on advancing differentiated cancer therapies, announced that it has engaged IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. Through the engagement, IBN will leverage its investor-focused distribution platform, including more than 5,000 syndication outlets, newsletters, social media channels, blogs and wire services via InvestorWire, to increase awareness of LIXTE’s first-in-class approach to enhancing the effectiveness of existing chemotherapy and immunotherapy treatments, including its lead clinical candidate, LB-100, across cancers with significant unmet medical need. To view the full press release, visit https://ibn.fm/xtCUR About LIXTE…

Continue Reading

FridayJan 09, 2026 12:57 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its announcement that milestone enrollment had been reached in the ongoing confirmatory Phase 3 FLASH2 trial of HyBryte(TM). The study focuses on the treatment of cutaneous T-cell lymphoma, with the overall blinded response rate standing at 48% for patients who have completed treatment. “In the Nov. 20, 2025, research report published by Zacks Small-Cap Research, expert analysis indicated strong conviction about the 50-patient enrollment milestone and…

Continue Reading

FridayJan 09, 2026 12:25 pm

BioMedNewsBreaks – FDA Clearance for HeartBeam Inc. (NASDAQ: BEAT) Highlighted in Medical Device Approvals Roundup

HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector.  HeartBeam's 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review. HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated in PatentVest’s…

Continue Reading

FridayJan 09, 2026 12:23 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus

Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… The contemporary view holds that nanocarrier-enabled formulations may be as transformative for drug delivery as the advent of monoclonal antibodies was for biologics… Into this context, Oncotelic Therapeutics, which in its most recent news has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its…

Continue Reading

ThursdayJan 08, 2026 9:20 am

BioMedNewsBreaks – VolitionRx Limited (NYSE American: VNRX) Study Shows Nu.Q Vet Feline Test Accurately Detects Lymphoma in Cats

VolitionRx (NYSE American: VNRX), a multinational epigenetics company, announced results from a clinical study demonstrating high accuracy of its Nu.Q Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, meaning no false positives, the blood-based assay detected more than 80% of feline lymphomas, supporting development of what the company expects to be the world’s first simple and affordable liquid biopsy test for feline cancer. The company stated that feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging after symptoms have progressed, and noted that…

Continue Reading

ThursdayJan 08, 2026 9:00 am

BioMedNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK

Lixte Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK’s Dostarlimab for the treatment of ovarian clear cell cancer. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the direction of Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its…

Continue Reading

WednesdayJan 07, 2026 12:11 pm

BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market 

Lixte Biotechnology Holdings (NASDAQ: LIXT) entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit, priced at the market under Nasdaq rules. The offering comprised 1,051,342 Common Units or Pre-Funded Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one Common Warrant exercisable at $3.96 per share, with the Common Warrants exercisable immediately and expiring 60 months from issuance. Gross proceeds totaled approximately $4.3 million, with net proceeds allocated for general corporate purposes and working capital. Spartan Capital Securities…

Continue Reading